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A B S T R A C TThe decade since the completion of the sequencing of the human
genome has witnessed signiﬁcant advances in the incorporation of
genomic information in diagnostic, treatment, and reimbursement
practices. Indeed, as case in point, there are now several dozen
commercially available genomic tests routinely applied across a wide
range of disease states in predictive or prognostic applications.
Moreover, many involved in the advancement of personalized med-
icine would view emerging approaches to stratify patients in mean-
ingful ways beyond genomic information as a signal of the progress
made. Yet despite these advances, there remains a general sense of
dissatisfaction about the progress of personalized medicine in terms
of its contribution to the drug development process, to the efﬁciency
and effectiveness of health care delivery, and ultimately to the
provision of the right treatment to the right patient at the right time.
Academicians, payers, and manufacturers alike are struggling not
only with how to embed the new insights that personalized medicine
promises but also with the fundamental issues of application in early
drug development, implications for health technology assessment,
new demands on traditional health economic and outcomes research
methods, and implications for reimbursement and access. In fact,
seemingly prosaic issues such as the deﬁnition and composition of
the term “personalized medicine” are still unresolved. Regardless of
these issues, practitioners are increasingly compelled to ﬁnd practicalsee front matter Copyright & 2013, International S
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, USA.solutions to the challenges and opportunities presented by the
evolving face of personalized medicine today. Accordingly, the articles
comprising this Special Issue offer applied perspectives geared toward
professionals and policymakers in the ﬁeld grappling with developing,
assessing, implementing, and reimbursing personalized medicine
approaches. Starting with a framework with which to characterize
personalized medicine, this Special Issue proceeds to illuminate
issues related to the intersection of personalized medicine and
comparative effectiveness; use of personalized medicine approaches
in drug development; methodological challenges; and payer
approaches to evaluation and reimbursement of pharmacodiagnostics
in the United States and Europe. It concludes with a look ahead,
underscoring current controversies yet to be resolved along with their
implications for further research and policy. It is hoped that these
articles will help inform the daily challenges faced by the Interna-
tional Society for Pharmacoeconomics and Outcomes Research
(ISPOR) community as it collectively addresses what promises to be
a new era in drug development and health care delivery.
Keywords: health economics and outcomes research, personalized
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Outcomes Research (ISPOR). Published by Elsevier Inc.In the decade since the sequencing of the human genome,
personalized medicine has been the focus of a growing body of
bench, health services, and health policy research. Indeed, in
2003, the year the Human Genome Project completed its sequenc-
ing, there were approximately 250 peer-reviewed articles pub-
lished under the topic of “personalized medicine.” By 2012, this
had grown to nearly 2500 articles annually, 10 times the pub-
lication rate of the previous decade [1]. As the implications of
truly “personalized” medicine came to be appreciated by policy-
makers and practitioners, talk ensued of a “brave new world” of
personalized care. Typically, the leading advocacy organization
refers to a new “age of personalized medicine,” the application of
which can “address the most critical challenges of our day” [2].
Despite this real progress, matching the sometimes polemic
nature of the discourse around personalized medicine to theactual changes witnessed in health care delivery can leave the
average practitioner confused. Compounding this confusion is
the lack of consensus around deﬁnitions and nomenclature.
Some argue that personalized medicine is deﬁned strictly in the
context of a genomic test, with a heavy focus on companion
diagnostics. For example, the Personalized Medicine Special
Interest Group of the ISPOR deﬁnes personalized medicine as
the use of genetic or other biomarker information to improve the
safety, effectiveness, and health outcomes of patients via more
efﬁciently targeted risk stratiﬁcation, prevention, and tailored
medication and treatment-management approaches [3]. Others
underscore aspects of “stratiﬁed medicine” that emphasize sub-
populations deﬁned in many disparate ways, not simply by
genomic information, and whose orientation is somewhat less
“personal” but more “population-based” [4].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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are perhaps typical when a new body of science is in the formu-
lative “norming”—indeed storming—stages. Such second-order dis-
course, however, can serve to obfuscate the current pressing issues
at hand and impede the ability of practitioners in outcomes
research, reimbursement, and delivery to get on with the tasks at
hand, including incorporating early genomic information in the
drug development process; evolving health economic and outcomes
research methodologies to match the new opportunities and
challenges of personalized medicine; grappling with coverage and
reimbursement decisions; and addressing the “lag” between current
regulatory practices and health systems needs in actual practice.
It is this gap that the current ISPOR Special Issue on Personal-
ized Medicine seeks to ﬁll. In 2011, the Institutional Council of
ISPOR, composed of industry, payer, and academic leaders from
across the heath care continuum, prioritized personalized medi-
cine as a key growth opportunity for ISPOR membership and
beyond. The orientation taken was to use the expertise of the
Council, in a peer reviewed context, to elicit actual and emerging
practices and novel use cases in the area of personal/stratiﬁed
medicine to help foster greater understanding among practitioners
of issues, best practices, barriers, and enablers to help advance a
critical area of health care delivery that at times appears mired in
doctrinal and operational difﬁculties.
Accordingly, the ﬁrst article in the Special Issue seeks to bring
together various threads in deﬁnition and nomenclature to advance
a basic framework with which to support the subsequent discus-
sion, and which thereby may also be of service to the broader
practitioner community seeking some level of consensus upon
which to engage in increment health systems adaptation. Redekop
and Mladsi proffer a framework starting from a series of applied
clinical questions that researchers, practitioners, and policymakers
confront on a daily basis relating to susceptibility, diagnosis,
prognosis, treatment, and surveillance. From there, the authors
show the linkages between these classic clinical questions and how
various personalized medicine technologies inﬂuence decision
making and ultimately patient care and outcome.
The Special Issue also addresses emerging methodological
issues focused in three broad (sometimes overlapping) areas:
applications in comparative effectiveness research (CER), drug
development, and economic evaluation. With respect to CER, it
becomes clear to even the casual observer that variation in patient
populations impact outcome and thus can have profound impli-
cations for evidence generation, its utilization, and the overlay of
economic considerations. In the end, Willke and colleagues see
personalized medicine as somewhat synonymous with the hetero-
geneity of treatment effect CER seeks to understand, if only to
control for while pursuing key health services research questions.
Personalized medicine has presented a brand new set of chal-
lenges and opportunities in the drug development process, and
manufacturers have faced a classic “institutional lag” in which
standard operating procedures and organizational boundaries are
having to give way to new processes and procedures through which
to identify, understand, and embed personalized medicine insights.
New entities such as centers of excellence in personalized medicine
have evolved to help companies come to grips with the emerging
imperatives, while advancing even broader but interrelated initia-
tives such as translational medicine. In the midst of this change,
health economics and outcomes research professionals ﬁnd them-
selves in the sometimes unenviable position of assuming new
accountabilities, for example, in the use of observational research
methods to understand the associations between stratiﬁcation of
patient populations, risk, prognosis, and outcome. As Burns and
colleagues highlight, in this context exciting new perspectives are
being advanced, or tried and true methods are being redeployed, to
assist in understanding the predictive and prognostic properties of
biomarkers, their accurate measurement, their sensitivity andspeciﬁcity, and ultimately their ability to change patient and
physician behavior in actual practice.
In a similar fashion, personalized medicine offers the prom-
ise, as evinced in emerging economic evaluation studies, to point
the way to greater efﬁciency and effectiveness in health care. A
number of leading thinkers in this area, at both the “macro” and
“micro” economic policy levels (some of whom have joined this
Special Issue), have showcased how personalized medicine can
help target appropriate patients, but more important, how this
can yield positive net beneﬁt to manufacturers, payers, and
governments as a whole. As Annemans, Redekop, and Payne
note herein, these new methods, or rather, redeployed methods
of economic evaluation, will help the ecosystem move beyond
stale arguments related to the dangers of “niching” products and
restricting patient choice and access, to explore win-win
approaches that appropriately value new technologies, both at
the time of launch and possibly over time.
In the US payer environment, arguably the most active
current reimbursement space for personalized medicine, emerg-
ing issues and use cases abound and in this Special Issue Frueh
felt it important to illuminate and contrast the way in which US
payers have opportunistically at times embraced personalized
medicine approaches, against current regulatory barriers and
practice inertia. The case of warfarin “metabolizers” in the
context of the next-generation antiplatelets is particularly illumi-
nating because it juxtaposes the limits of basic science, compel-
ling payer interest in controlling costs, and ultimately the
challenging dynamic of inﬂuencing practice patterns on the basis
of an imperfect, and at best, emerging evidence base. Similarly, in
Europe, the continuing austerity has brought to the fore serious
challenges, and indeed dissention, about who should bear the
costs of personalized medicine and in what manner. The
advanced health technology assessment (HTA) “regimes” in
Europe have been highly active in assessing the merits of
personalized medicine technologies and approaches, and have
perhaps inadvertently brought to the fore controversy that
unresolved could serve to stiﬂe further evolution in the area
and impede creative approaches that could yield positive value to
the broader ecosystem. Here Payne and Annemans underscore
the need to assess societal, patient, and providers perspectives
when evaluating companion diagnostics, along with the limits to
HTA decision making imposed by weak clinical and economic
evidence bases. Perspectives vary as well, they observe, when
considering national HTA decisions versus subnational, some-
times mediated by “supplier” versus “consumer” utility (e.g.,
academic community vs. patients). They conclude with several
key recommendations for Europe to foster a more receptive
climate for personalized medicine, recognizing that its positive
beneﬁts are conferred to patient, provider, and payer alike.
With these key issues helping to characterize the current “state
of the state,” we conclude this Special Issue with a look ahead at
emerging trends and the need for future research. A broad set of
opportunities is addressed, with emphasis on evidentiary needs
ex ante and ex post stratiﬁcation, regulatory gaps, and evidence of
clinical utility in actual practice. Notably, Towse and Garrison argue
that raising the threshold for evidence will mean less pharmaco-
diagnostic research and development unless reimbursement and
intellectual property demands are kept realistic.
Thomas Kuhn in his classic work the Structure of Scientiﬁc
Revolutions [5] cites not dramatic advances, like the sequencing of
the human genome, as the key drivers of scientiﬁc progress, but
rather the incremental learnings that illuminate inadequacies of
current scientiﬁc dogma, which, in turn, prepare the ground for
revolutionary change. As this Special Issue in some measure
conveys, we believe that we ﬁnd ourselves within that incremen-
tal process that has the potential to usher in a scientiﬁc
revolution, and with appropriate foresight and integration, health
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) S 1 – S 3 S3economics and outcomes research professionals in academia,
industry, and payer systems will play a central role.
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